Objective-To investigate the possible therapeutic role of omeprazole, a powerful proton pump inhibitor, in unselected patients presenting with upper gastrointestinal bleeding.
histamine H2 receptor antagonists8 and fibrinolytic inhibitors" may confer therapeutic benefit. Histamine H2 receptor antagonists seem to reduce rates of rebleeding, operation, and death by about 10%, 20%, and 30% respectively.8 These observations suggest that inhibition of gastric acid secretion may be capable of influencing outcome. We therefore examined the hypothesis that profound suppression of gastric acid secretion with the proton pump inhibitor omeprazole decreases morbidity and mortality from acute upper gastrointestinal bleeding.
Omeprazole is the first available benzimidazole proton pump inhibitor with the capacity effectively to abolish acid secretion. 4 We have shown that a regimen ofhigh dose intravenous omeprazole causes a rapid and profound inhibition of acid secretion."5 We report the results of a randomised double blind placebo controlled clinical trial of its effectiveness in patients presenting with haematemesis or melaena.
Patients and methods
We examined the death, rebleeding, and operation rates and transfusion requirements in patients admitted to University and City Hospitals, Nottingham, with upper gastrointestinal bleeding between May 1986 and November 1989. Rebleeding was defined as overt haematemesis; passage of fresh blood from the rectum; a fall in haemoglobin concentration of more than 20 g/l within any 24 hour period after the first 24 hours; shock in the presence of continuing melaena; or the presence of fresh blood in the stomach or duodenum, or both, at repeat endoscopy when further bleeding was suspected.
All patients with overt upper gastrointestinal bleeding or a history of haematemesis or melaena, or both, within 24 hours preceding admission were eligible for entry into the study provided they did not meet any of the exclusion criteria. These criteria were age below 18 years; pregnant; the presence of severe physical illness making active treatment according to the protocol inappropriate (for example, terminal disease or advanced malignancy); bleeding of such severity that immediate surgery was indicated; trivial bleeding such that active management was unnecessary; bleeding developing in patients who had'-been admitted to hospital for other reasons; previous participation in the study; inability to start treatment within 12 hours of admission; and potential for drug interactions-for example patients taking phenytoin and warfarin. Ethical approval was obtained from the Nottingham hospitals ethics committees. Wherever possible eligible patients gave verbal consent to inclusion in this study and patients who were unwilling to participate were not enrolled. Consent was not sought from patients who were too unwell to understand the study's aims. Trial treatment was stopped and the patient withdrawn if the patient was considered not to have had upper gastrointestinal bleeding; severe medical problems developed that necessitated breaking the treatment code; the patient was unwilling to continue in the study; or there was non-compliance with the study protocol. Interim analyses of overall mortality, based on the O'Brien and Fleming procedure for group sequential tests,'6 were performed by an independent statistician after 200 and 500 patients had completed the trial in order to screen for unsuspected hazards associated with omeprazole.
REVIEW OF DEATHS
A final diagnosis was assigned to each patient at death or discharge on the basis of details available in the clinical record form. In addition, the hospital records and necropsy reports of all patients who had died during the trial were reviewed by RFAL and CJH to confirm the cause of upper gastrointestinal bleeding and assess the contribution bleeding had made to death. This review was carried out before the randomisation code was broken. Deaths were categorised as follows. (1) (5) Upper gastrointestinal bleeding was incidental to the condition leading to death (for example, death from stroke secondary to pre-existing thrombocytopenia). (6) Significant upper gastrointestinal bleeding never shown -normal appearance on endoscopy and no fall in haemoglobin concentration. This included deaths where bleeding was shown to arise from beyond the duodenum. Some of these patients were classified as "other" or "'cause unclear" in the primary endoscopic diagnosis and whose final diagnosis was based on review of case records. (7) Death where gastroduodenal perforation followed bleeding. (8) Otherscauses of death not classified above (for example, carcinoma of pancreas).
Deaths were categorised according to whether the cause of bleeding was from duodenal ulceration, gastric ulceration, gastric erosions, oesophageal ulceration or oesophagitis, gastric cancer, oesophageal varices, abnormalities distal to the descending duodenum, and other or unknown causes.
STATISTICAL ANALYSIS
All study variables were analysed according to intention to treat. Main variables were also analysed by the per protocol approach, in which patients violating the protocol regulations were excluded. All decisions on exclusion of patients from analysis were taken before breaking the treatment code.
Mortality in all patients and in the subgroup of patients with confirmed upper gastrointestinal bleeding and in those with gastric and duodenal ulcers was analysed. The associations between trial treatment, treatment centre, age (s,54, 55-64, >64 years) , initial systolic blood pressure (-100, >100 mm Hg), and bleeding site (gastric ulcer, duodenal ulcer, other) and rebleeding, operation, and death were examined.
The proportion of patients with each outcome (death, operation, etc) was analysed with the MantelHaenszel test stratified by centre.'7 Continuous variables were tested by Wilcoxon tests stratified by centre. Confidence intervals for proportions were calculated by using the standard normal approximation. The effect of possible prognostic factors on binary variables (mortality, operation, and rebleeding) was analysed by logistic regression models.'7 The sample size (1100 patients) was based on an assumption of a reduction of mortality from all causes by omeprazole from 10% to 5% (ac=0-05, 1 -f3=0 8, two tailed significance).'8
Results
We randomised 1154 patients into the study. Four of these patients were not given the study treatment (one omeprazole group, three placebo group) and in three the treatment given could not subsequently be clearly identified. The remaining 1147 patients were successfully randomised to receive omeprazole (n=578) BMJ VOLUME 304
18 JANUARY 1992or placebo (n= 569). Of these, 698 patients were admitted to University Hospital and 449 to City Hospital. 16 (11) entered the trial for a second time, 15 started treatment more than 12 hours after admission, and three were under age or possibly pregnant) leaving 529 on placebo and 520 on omeprazole available for per protocol analysis. Table II shows the primary endoscopic and final diagnoses: the distribution of disease randomised to each treatment was similar.
CLINICAL OUTCOME Table III shows the outcome in patients analysed by intention to treat. Patients receiving omeprazole had slightly lower transfusion requirements and rebleeding rates than control patients, but these differences were not significant. Moreover, the death rate was slightly higher in patients who received omeprazole (6-9%) compared with those treated with placebo (5 3%), though the difference was not significant. Table III also shows the outcome in 1049 patients included in the per protocol analysis. Results in these patients were similar to those obtained in the intention to treat analysis. Results in the 945 patients with confirmed upper gastrointestinal bleeding (477 omeprazole, 468 placebo) also showed a similar pattern of results. In this group 29 (6-1%; 95% confidence interval 4 0% to 8 2%) of those who received omeprazole and 23 (4 9%; 2 9% to 6 9%) of those who received placebo died (NS). Table IV shows that the pattern of results in patients with peptic ulcers was.elso generally similar to that seen in the group as a whole. There was an excess of deaths in patients with duodenal ulcer treated with omeprazole rather than placebo (16 v eight), but this difference was not significant. A total of 155 patients (73 omeprazole group, 82 placebo group) was taking aspirin or non-aspirin non-steroidal antiinflammatory drugs. Of these, 91 had ulcers (41 omeprazole group, 50 placebo group). Sixteen (10%) of the 155 patients died (nine in omeprazole group, seven in placebo group). All but two of the patients taking non-steroidal anti-inflammatory drugs who died had peptic ulcers. Of patients with oesophageal varices, three who received omeprazole and three who received placebo died. Thirty nine patients received endoscopic treatment (15 in omeprazole group, 17 in placebo group); treatment was of variceal sclerotherapy (20 patients) or treatment of ulcer bleeding by diathermy, heater probe, or sclerotherapy (11 with duodenal ulcer, four with gastric ulcer). Five of the patients who received endoscopic treatment died (three in omeprazole group, two in placebo group).
ADJUSTMENT FOR AGE AND OTHER PROGNOSTIC FACTORS
The group treated with omeprazole were slightly older than the placebo treated group (table I) . Standardising the mortality according to the bands in table I resulted in a small reduction in mortality in the omeprazole group to 6-7% (95% confidence interval 4-6% to 8 8%) with no change in the placebo group at 5.3% (3 4% to 7 3%).
Logistic regression was used to analyse the combined effects of age, initial systolic blood pressure, bleeding site, centre, and treatment group on rates of rebleeding, operation, and death. For all three outcomes increasing age (p<00001) and a low initial systolic blood pressure (p<0001) were the strongest prognostic factors. The presence of a gastric or duodenal ulcer was a significant factor for rebleeding (p<001) and operation (p<0 005) but not for death (p=0-12). The treatment centre was unrelated to all three outcomes. Relations between treatment groups and rebleeding (p=0 10), operation (p=064), or mortality (p=0 33) were not significant.
RESULT OF ENDOSCOPY
In contrast with the results concerning rates of rebleeding, operation, an'd death, treatment with BMJ VOLUME 304 18 JANUARY 1992 omeprazole was associated with a highly significant reduction in the incidence of endoscopic signs of bleeding (table V) . Patients who received omeprazole had lower rates of blood in the stomach, active bleeding, red clot on the lesion, and black spots on the lesion than patients receiving placebo. 
